Diagnostic Methods in Australia
In Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011, the Federal Court confirmed that diagnostic methods are patentable subject-matter in Australia. This will be a satisfying result for...
In Sequenom, Inc. v Ariosa Diagnostics, Inc. FCA 1011, the Federal Court confirmed that diagnostic methods are patentable...
Read More
China Government Releases New Regulation on Human Genetic Resource
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on July 1. For the life sciences industry and research organizations...
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on...
Read More
Pharmaceutical patents: Fighting a $25 million claim for damages
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia will calculate damages in proceedings concerning the infringement of a...
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia...
Read More
判例研究: H Lundbeck A/S & Anor v Sandoz Pty Ltd
オーストラリア連邦裁判所 は、最近の判決で、たとえジェネリック企業が関連特許の標準の特許期間が満了した後に医薬品の発売を開始しても、特許期間が延長される可能性が依然として存在する環境下では、後日特許期間の延長が認められた場合に重大なリスクが伴い得ることを示しました。
オーストラリア連邦裁判所 は、最近の判決で、たとえジェネリック企業が関連特許の標準の特許期間が満了した後に医薬品の発売を開始しても、特許期間が延長される可能性が依然として存在する環境下では、後日特許期間の延長が認められた場合に重大なリスクが伴い得ることを示しました。
Read More
New Zealand Update: ACTIPHEN Too Similar to ACTAZIN to Register
Anagenix opposed the Pharmazen’s application to register ACTIPHEN in connection with a range of medicinal food preparations (Class 5) and printed materials relating to those goods (Class 16).
Anagenix opposed the Pharmazen’s application to register ACTIPHEN in connection with a range of medicinal food preparations (Class 5)...
Read More
Case Note: H Lundbeck A/S & Anor v Sandoz Pty Ltd
A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by a generic company even after expiry of the standard term...
A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by...
Read More
Sigma Pharmaceuticals Case Clarifies Aspects of Compensable Loss
The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth FCA 1556 has clarified, among other things, a number of issues concerning compensation arising from the usual...
The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth FCA 1556 has clarified, among other things,...
Read More